GENE ONLINE|News &
Opinion
Blog

2022-04-22| Licensing

Emerging NY Biotech Furthers Sanofi’s CNS Therapeutics

by Fujie Tham
Share To

A novel New York-based biotech managed to impress Sanofi, snatching a deal to obtain two Phase III CNS pipelines. In a brief press release, not much was disclosed about the scope of the deal, it included an upfront payment, but specific financial details of the deal were not revealed.

Terran Biosciences, dedicated to the development of transformational therapeutics for neurological diseases, secured the agreement with Sanofi for exclusive global rights to develop and market said two late-stage CNS assets. These therapeutics generated 4 Investigational New Drug (IND) applications and more than 104 clinical studies involving over 15,000 subjects across numerous CNS indications.

Terran plans to rapidly advance development of these new pipelines for neurological and psychiatric indications with novel applications for large unmet medical demands. This transaction represents a major next stage in the development of these promising portfolios.

“We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry,” said Dr. Sam Clark, Terran’s Founder and CEO.

Related Article: Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

 

Mysterious NY Biotech

 

Equipped with a bare corporate webpage, little is known about Terran Biosciences. Known investors include Noetic Fund and Catalytic Impact Foundation. The biotech also popped up in March recently to sign a CNS “portfolio” and intellectual properties deal with Concert.

Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing a number of late-stage assets, which include novel psychedelic-based therapeutics.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
FDA Panel Suggests Redesigning Vaccines to Target Omicron Variants, Pfizer & Sanofi Share Booster Updates
2022-06-29
Sanofi’s New Pompe Disease Treatment Wins Approval in Europe
2022-06-29
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top